Daré Bioscience (NASDAQ:DARE – Get Free Report) is expected to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $1.00 million for the quarter.
Daré Bioscience Trading Down 0.3 %
Shares of DARE stock opened at $2.96 on Thursday. The company’s 50-day moving average price is $3.13 and its 200-day moving average price is $3.32. The stock has a market cap of $25.75 million, a price-to-earnings ratio of -5.01 and a beta of 1.38. Daré Bioscience has a twelve month low of $2.67 and a twelve month high of $7.56.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Daré Bioscience in a research report on Tuesday, December 17th.
About Daré Bioscience
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Further Reading
- Five stocks we like better than Daré Bioscience
- Why Are These Companies Considered Blue Chips?
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- What is Put Option Volume?
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Technology Stocks Explained: Here’s What to Know About Tech
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
